CLPP-2068

CAT: 0804-HY-173048-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-173048-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CLPP-2068 is the orally active activator for human caseinolytic protease P (HsClpP) with an EC50 of 50.4 nM. CLPP-2068 exhibits anti-proliferative efficacy in OCI-LY10 cancer cell with an IC50 of 5.2 nM. CLPP-2068 decreases mitochondrial membrane potential, increases mitochondrial ROS levels, and induces mitochondrial dysfunction. CLPP-2068 arrests the cell cycle at G1 phase, and induces apoptosis in cell OCI-LY10. CLPP-2068 exhibits antitumor activity in mouse xenograft models[1].
UNSPSC
12352005
Target
Apoptosis; ClpP; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer
Purity
97.41
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1NC(NCC2=CC=C(Br)C=C2)=NC3=C1CN([C@H](C)C3)CC4=CC(C#N)=CC=C4
Molecular Formula
C23H22BrN5O
Molecular Weight
464.36
References & Citations
[1]Sun M, et al., Harnessing the Magic Methyl Effect: Discovery of CLPP-2068 as a Novel HsClpP Activator for the Treatment of Diffuse Large B-Cell Lymphoma. J Med Chem. 2025 Feb 27;68 (4) :4287-4307.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products